Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 157-163

  Zelina, Shannon ^a   Sheen, Chih Wei ^a   Radzio, Jessica ^a   Mellors, John W ^a   Sluis Cremer, Nicolas ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ASPARTIC ACID; DEOXYCYTIDINE TRIPHOSPHATE; GLYCINE; LAMIVUDINE; LAMIVUDINE TRIPHOSPHATE; LEUCINE; METHIONINE; PRIMER DNA; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THREONINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; VALINE; ZIDOVUDINE; ZIDOVUDINE MONOPHOSPHATE;

ANTIBIOTIC RESISTANCE; ARTICLE; ENZYME ACTIVITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STEADY STATE; THERMODYNAMICS; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; LAMIVUDINE; MODELS, MOLECULAR; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; THERMODYNAMICS; ZIDOVUDINE;

EID: 37849050932     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00904-07     Document Type: Article

References (41)

1. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15911.
2. Bartlett, J. A., S. L. Benoit, V. A. Johnson, J. B. Quinn, and G. E. Sepulveda. 1996. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125:161-172.
3. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2002. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations. J. Virol. 76:3248-3252.
4. Brehm, J., D. Koontz, N. Sluis-Cremer, and J. W. Mellors. 2007. HIV-1 reverse transcriptase mutations A371V and Q509L decrease DNA-dependent RNase H cleavage and increase the rate of AZT-MP excision. Antiviral Ther. 12:S124.
5. Canard, B., S. R. Sarfati, and C. C. Richardson. 1998. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′- monophosphate-terminated primer. J. Biol. Chem. 273:14596-14604.
6. Deval, J., J. M. Navarro, B. Selmi, J. Courcambeck, J. Boretto, P. Halfon, S. Garrido-Urbani, J. Sire, and B. Canard. 2004. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J. Biol. Chem. 279:25489- 25496.
7. Deval, J., B. Selmi, J. Boretto, M. P. Egloff, C. Guerreiro, S. Sarfati, and B. Canard. 2002. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using α-boranophosphate nucleotide analogues. J. Biol. Chem. 277:42097-42104.
8. Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambeck, P. Halfon, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279:509-513.
9. Divita, G., B. Muller, U. Immendorfer, M. Gautel, K. Rittinger, T. Restle, and R. S. Goody. 1993. Kinetics of interaction of HIV reverse transcriptase with primer/template. Biochemistry 32:7966-7971.
10. + cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
11. Feng, J. Y., and K. S. Anderson. 1999. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38:9440-9448.
12. Gallego, O., A. Corral, C. de Mendoza, B. Rodes, and V. Soriano. 2002. Prevalence of G333D/E in naive and pretreated HIV-infected patients. AIDS Res. Hum. Retrovir. 18:857-860.
13. Galli, R., B. Sattha, G. Tachedjian, and P. R. Harrigan. 2004. Beyond codon 240: mutations in the HIV-1 reverse transcriptase selected after exposure to antiretrovirals. 15th International AIDS Conference, Bangkok, Thailand.
14. Girouard, M., K. Diallo, B. Marchand, S. McCormick, and M. Gotte. 2003. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. J. Biol. Chem. 278:34403-34405.
15. Götte, M., D. Arion, M. A. Parniak, and M. A. Wainberg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74:3579-3585.
16. Ignatov, M. E., A. J. Berdis, S. F. Le Grice, and M. D. Barkley. 2005. Attenuation of DNA replication by HIV-1 reverse transcriptase near the central termination sequence. Biochemistry 44:5346-5356.
17. Johnson, K. A. 1995. Rapid quench kinetic analysis of polymerases, adenosinetriphosphatases, and enzyme intermediates. Methods Enzymol. 249:38-61.
18. Kagan, R., M. Winters, T. Merigan, and P. Heseltine. 2004. Expanded range of HIV-1 reverse transcriptase mutations detected through long range sequencing. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
19. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997.
20. Katlama, C., D. Ingrand, C. Loveday, N. Clumeck, and J. Mallolas. 1996. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 276:110-118.
21. Kemp, S. D., C. Shi, S. Bloor, P. R. Harrigan, J. W. Mellors, and B. A. Larder. 1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J. Virol. 72:5093-5098.
22. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
23. Kuritzkes, D. R., J. B. Quinn, S. L. Benoit, D. L. Shugarts, and A. Griffin. 1996. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10:975-981.
24. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
25. Le Grice, S. F., C. E. Cameron, and S. J. Benkovic. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144.
26. Le Grice, S. F., and F. Gruninger-Leitch. 1990. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187:307-314.
27. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43.
28. Miranda, L. R., M. Gotte, F. Liang, and D. R. Kuritzkes. 2005. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob. Agents Chemother. 49:2648-2656.
29. Naeger, L. K., N. A. Margot, and M. D. Miller. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Ther. 6:115-126.
30. Nikolenko, G. N., K. A. Frankenberry, S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak. 2005. RNase H domains obtained from treatment-experienced patients increase resistance to AZT. Antiviral Ther. 10:S89.
31. Nikolenko, G. N., K. A. Frankenberry, S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak. 2006. The HIV-1 reverse transcriptase connection domain from treatment-experienced patients contributes to AZT resistance. Antiviral Ther. 11:S142.
32. Nikolenko, G. N., S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak. 2005. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 102:2093-2098.
33. Parniak, M. A., and N. Sluis-Cremer. 2000. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol. 49:67-109.
34. Reardon, J. E. 1992. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31:4473-4479.
35. Sarafianos, S. G., A. D. Clark, Jr., K. Das, S. Tuske, and J. J. Birktoft. 2002. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21:6614-6624.
36. Selmi, B., J. Boretto, S. R. Sarfati, C. Guerreiro, and B. Canard. 2001. Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an α-boranophosphate nucleoside analogue. J. Biol. Chem. 276:48466-48472.
37. Shi, C., and J. W. Mellors. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41:2781-2785.
38. Sluis-Cremer, N., D. Arion, U. Parikh, D. Koontz, R. F. Schinazi, J. W. Mellors, and M. A. Parniak. 2005. The 3′-azido group is not the primary determinant of 3′-azido-3′-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J. Biol. Chem. 280:29047-29052.
39. Sluis-Cremer, N., C. W. Sheen, S. Zelina, P. Argoti Torres, U. Parikh, and J. W. Mellors. 2007. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 51:48-53.
40. Stoeckli, T. C., S. MaWhinney, J. Uy, C. Duan, and J. Lu. 2002. Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob. Agents Chemother. 46:4000-4003.
41. Yap, S. H., B. Wynhoven, M. Kuiper, C. W. Sheen, N. Sluis-Cremer, R. Harrigan, and G. Tachedjian. 2007. A mutation in the connection subdomain of the HIV-1 reverse transcriptase (N348I) is selected commonly in vivo and confers decreased susceptibility to zidovudine and nevirapine. 14th Conference on Retrovirus and Opportunistic Infections, Los Angeles, CA.